Cargando…
Study protocol of a multicentre, randomised, controlled trial evaluating the effectiveness of probiotic and peanut oral immunotherapy (PPOIT) in inducing desensitisation or tolerance in children with peanut allergy compared with oral immunotherapy (OIT) alone and with placebo (the PPOIT-003 study)
INTRODUCTION: Peanut allergy is the the most common cause of life-threatening food-induced anaphylaxis. There is currently no effective long-term treatment. There is a pressing need for definitive treatments that improve the quality of life and prevent fatalities. Allergen oral immunotherapy (OIT) i...
Autores principales: | Chebar Lozinsky, Adriana, Loke, Paxton, Orsini, Francesca, O’Sullivan, Michael, L. Prescott, Susan, Gold, Michael S, Quinn, Patrick, DunnGalvin, Audrey, LK Tang, Mimi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482477/ https://www.ncbi.nlm.nih.gov/pubmed/32912942 http://dx.doi.org/10.1136/bmjopen-2019-035871 |
Ejemplares similares
-
Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study)
por: Loke, Paxton, et al.
Publicado: (2021) -
Transitioning peanut oral immunotherapy to clinical practice
por: Lazizi, S., et al.
Publicado: (2022) -
Transitioning from epicutaneous to oral peanut immunotherapy
por: Wong, Lauren, et al.
Publicado: (2023) -
Home-Based Peanut Oral Immunotherapy for Low-Risk Peanut-Allergic Preschoolers During the COVID-19 Pandemic and Beyond
por: Chua, Gilbert T., et al.
Publicado: (2021) -
Immune signatures predicting the clinical outcome of peanut oral immunotherapy: where we stand
por: Wanniang, Naphisabet, et al.
Publicado: (2023)